Clinically Approved Ion Channel Inhibitors Close Gates for Hepatitis C Virus and Open Doors for Drug Repurposing in Infectious Viral Diseases.

2.50
Hdl Handle:
http://hdl.handle.net/10033/620901
Title:
Clinically Approved Ion Channel Inhibitors Close Gates for Hepatitis C Virus and Open Doors for Drug Repurposing in Infectious Viral Diseases.
Authors:
Pietschmann, Thomas ( 0000-0001-5138-6239 )
Abstract:
Chronic hepatitis C virus (HCV) infection causes severe liver disease and affects ca. 146 million individuals. Novel directly acting antivirals targeting HCV have revolutionized treatment. However, high costs limit access to therapy. Recently, several related drugs used in humans to treat allergies or as neuroleptics emerged as potent HCV cell entry inhibitors. Insights into their antiviral modes of action may increase opportunities for drug repurposing in hepatitis C and possibly other important human viral infections.
Affiliation:
TwinCore, Zentrum für experimentelle und klinische Infektionsforschung GmbH, Feodor-Lynen Str. 7, 30625 Hannover, Germany.
Citation:
Clinically Approved Ion Channel Inhibitors Close Gates for Hepatitis C Virus and Open Doors for Drug Repurposing in Infectious Viral Diseases. 2017, 91 (2) J. Virol.
Journal:
Journal of virology
Issue Date:
15-Jan-2017
URI:
http://hdl.handle.net/10033/620901
DOI:
10.1128/JVI.01914-16
PubMed ID:
27807238
Type:
Article
Language:
en
ISSN:
1098-5514
Appears in Collections:
publications of the department experimental Virology([TC]EVIR)

Full metadata record

DC FieldValue Language
dc.contributor.authorPietschmann, Thomasen
dc.date.accessioned2017-04-21T10:35:55Z-
dc.date.available2017-04-21T10:35:55Z-
dc.date.issued2017-01-15-
dc.identifier.citationClinically Approved Ion Channel Inhibitors Close Gates for Hepatitis C Virus and Open Doors for Drug Repurposing in Infectious Viral Diseases. 2017, 91 (2) J. Virol.en
dc.identifier.issn1098-5514-
dc.identifier.pmid27807238-
dc.identifier.doi10.1128/JVI.01914-16-
dc.identifier.urihttp://hdl.handle.net/10033/620901-
dc.description.abstractChronic hepatitis C virus (HCV) infection causes severe liver disease and affects ca. 146 million individuals. Novel directly acting antivirals targeting HCV have revolutionized treatment. However, high costs limit access to therapy. Recently, several related drugs used in humans to treat allergies or as neuroleptics emerged as potent HCV cell entry inhibitors. Insights into their antiviral modes of action may increase opportunities for drug repurposing in hepatitis C and possibly other important human viral infections.en
dc.language.isoenen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.titleClinically Approved Ion Channel Inhibitors Close Gates for Hepatitis C Virus and Open Doors for Drug Repurposing in Infectious Viral Diseases.en
dc.typeArticleen
dc.contributor.departmentTwinCore, Zentrum für experimentelle und klinische Infektionsforschung GmbH, Feodor-Lynen Str. 7, 30625 Hannover, Germany.en
dc.identifier.journalJournal of virologyen

Related articles on PubMed

This item is licensed under a Creative Commons License
Creative Commons
All Items in HZI are protected by copyright, with all rights reserved, unless otherwise indicated.